FDA ready to loosen rules for clinical trials, allowing drug companies to make them up as they go along

Email this article to a friend

Printable Version

Articles Related to This Article: • Clinical Drug Trials: FDA Fails to Monitor Safety and Integrity • Warning Over Unfair Terms for Patients in Clinical Trials (press release) • Massive medical fraud exposed: pharmaceutical company paid doctors to prescribe drugs and run sham clinical trials Sign the Health Revolution Petition Join the call for genuine health freedom in America. End FDA tyranny and Big Pharma corruption. Watch the video and sign the petition here.

(NaturalNews) The U.S. Food and Drug Administration (FDA) announced today that drug makers will soon be able to conduct "adaptive" clinical trials that will allow researchers to change details of the study midway through.

Under the FDA's new guidelines, pharmaceutical companies conducting drug studies would no longer be required to follow the current rules, under which patients and physicians in drug trials do not know the results until the trial is complete. Those guidelines were put in place to prevent doctors and patients from purposely affecting the outcome of a study.

However, the FDA's new "adaptive" trials would allow drug makers to see early trial results midway through, permitting researchers to change study participants, or drop the study entirely if the drug seems ineffective. The new guidelines are aimed at reducing the cost of bringing new drugs to the market.

"These new approaches to clinical trials can result in trial designs that tell us more about safety and benefits of drugs, in potentially shorter time frames, exposing fewer people to experimental treatments," said Dr. Scott Gottlieb, deputy FDA commissioner of medical and scientific affairs.

"It may also be true that making decisions during a trial's course can increase the rate of making an erroneous decision," Gottlieb said. He also acknowledged that the newer designs could lead to "complicated decisions and uncertainty about the best approach for data analysis."

Critics of the FDA view the new guidelines as an opportunity for drug companies to more easily manipulate and falsify study findings to bring ineffective or dangerous drugs to the market simply to make a profit. With fraudulent clinical trials already commonplace, the new FDA rules would appear to make it even easier for drug companies to engineer clinical trials to produce any desired outcome.

###

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • Clinical Drug Trials: FDA Fails to Monitor Safety and Integrity • Warning Over Unfair Terms for Patients in Clinical Trials (press release) • Massive medical fraud exposed: pharmaceutical company paid doctors to prescribe drugs and run sham clinical trials	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/019615_clinical_trials_drug_companies_junk_science.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/019615_clinical_trials_drug_companies_junk_science.html">FDA ready to loosen rules for clinical trials, allowing drug companies to make them up as they go along</a>